MRSA
Reading File
Finding Sources
Finding Sources
Searching PubMed
"methicillin-resistant Staphylococcus aureus"[MeSH Terms] AND treatment
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
MRSA stands for methicillin-resistant Staphylococcus aureus.
It is a strain of S. aureus that is resistant to methicillin and most beta-lactam antibiotics (including many penicillins and cephalosporins), mainly due to the mecA gene encoding PBP2a. This altered penicillin-binding protein prevents beta-lactams from working effectively.
Book citation: Roberts and Hedges’ Clinical Procedures in Emergency, p. 865 to 866; Quick Compendium of Clinical Pathology 5th edition, p. 110 to 111
Book citation: Roberts and Hedges’ Clinical Procedures in Emergency, p. 865 to 866; Quick Compendium of Clinical Pathology 5th edition, p. 110 to 111
Key points:
- Commonly causes skin and soft tissue infections such as abscesses, furuncles, and cellulitis
- Can also cause invasive disease: bacteremia, pneumonia, osteomyelitis, endocarditis, surgical site infections
- Spreads in both community and healthcare settings
- Healthcare-associated MRSA is often more multidrug-resistant
- Community-associated MRSA (often USA300 lineage) may have virulence factors like PVL linked to aggressive necrotic skin infection and sometimes necrotizing pneumonia
Book citation: ROSEN's Emergency medicine Concepts and clinical practice, p. 2401; Sherris & Ryan's Medical Microbiology, Eighth Edition, p. 984; GOLDMAN-CECIL MEDICINE INTERNATIONAL EDITION, 2 VOLUME SET, p. 1887
Typical treatment approach (depends on infection severity/site and local resistance):
- Small abscesses: incision and drainage is often central
- Oral options for uncomplicated MRSA SSTI often include TMP-SMX, doxycycline/minocycline, or clindamycin (if susceptibility supports it)
- Severe/invasive infection: IV agents such as vancomycin are commonly used, with alternatives like linezolid or daptomycin in selected cases
- Always tailor to culture/susceptibility and clinical context
Book citation: ROSEN's Emergency medicine Concepts and clinical practice, p. 2401 to 2402
Infection control and prevention:
- Hand hygiene, contact precautions, cleaning of shared equipment/surfaces
- In higher-risk hospital units, screening and decolonization strategies can reduce transmission
- Typical decolonization regimens involve chlorhexidine bathing and intranasal mupirocin in selected settings
Book citation: Harrison’s Principles of Internal Medicine 22E, p. 1195 to 1196
Recent evidence check (last 2 years):
I screened PubMed for systematic reviews/meta-analyses. No major contradiction to core textbook principles was identified in the quick scan, but recent reviews continue to refine antibiotic comparative effectiveness and special-population management (for example PMIDs: 38789000, 38145631).
If you want, I can give you:
- a patient-friendly explanation,
- an exam-style high-yield summary, or
- a practical empiric treatment table by syndrome (SSTI, pneumonia, bacteremia).
2 and 3 both
2) Exam-style high-yield MRSA summary
Definition
- MRSA = methicillin-resistant Staphylococcus aureus
- Resistance mechanism: mecA gene -> altered PBP2a -> resistance to most beta-lactams
Book citation: Quick Compendium of Clinical Pathology 5th edition, p. 110 to 111
Epidemiology
- Both community-associated (CA-MRSA) and healthcare-associated (HA-MRSA)
- CA-MRSA is a major cause of purulent skin/soft tissue infection in many ED settings
- HA-MRSA linked to invasive/device-related/hospital infections
Book citation: ROSEN's Emergency medicine Concepts and clinical practice, p. 2401; Harrison’s Principles of Internal Medicine 22E, p. 1195 to 1196
Virulence and microbiology
- CA lineages (for example USA300) often carry PVL and can behave aggressively in skin disease
- HA-MRSA tends to be more multidrug-resistant
Book citation: Sherris & Ryan's Medical Microbiology, Eighth Edition, p. 984; GOLDMAN-CECIL MEDICINE INTERNATIONAL EDITION, 2 VOLUME SET, p. 1887
Clinical syndromes
- Purulent SSTI: abscess, furuncle, cellulitis with pus
- Invasive disease: bacteremia, endocarditis, osteomyelitis, pneumonia, surgical-site infection
- Rare but severe: necrotizing fasciitis or necrotizing pneumonia
Book citation: ROSEN's Emergency medicine Concepts and clinical practice, p. 2401 to 2402
Diagnostics pearls
- Culture purulent material when possible
- MRSA detection methods include cefoxitin-based phenotypic testing, PBP2a assays, PCR
- If erythromycin-resistant but clindamycin-susceptible, check inducible clindamycin resistance (D-test)
Book citation: Quick Compendium of Clinical Pathology 5th edition, p. 110 to 111
Core management principles
- Source control first for purulent disease (incision and drainage)
- Add antibiotics based on severity, host risk, and local antibiogram
- Severe/invasive disease usually requires IV MRSA-active therapy
Book citation: ROSEN's Emergency medicine Concepts and clinical practice, p. 2401 to 2402
Infection prevention
- Hand hygiene, contact precautions, environmental cleaning
- In high-risk units/outbreaks: screening plus decolonization strategies (for selected populations)
Book citation: Harrison’s Principles of Internal Medicine 22E, p. 1195 to 1196
3) Practical empiric MRSA treatment table by syndrome
Use local guidelines/antibiogram, renal function, allergy history, and illness severity to finalize therapy.
| Syndrome | Typical empiric MRSA-active options | Key practical notes |
|---|---|---|
| Uncomplicated purulent SSTI (small abscess, stable patient) | I&D alone may be sufficient in selected cases; if antibiotics needed: TMP-SMX, doxycycline/minocycline, clindamycin (if susceptible) | I&D is central. Clindamycin needs attention to inducible resistance (D-test). |
| Moderate-severe SSTI / failed outpatient / systemic signs | IV vancomycin first-line in many settings; alternatives: linezolid, daptomycin (non-pneumonia), ceftaroline | Hospitalize if unstable, deep infection, immunocompromised, or high-risk site. |
| MRSA pneumonia (especially severe/HAP/VAP risk) | Vancomycin or linezolid | Daptomycin is not used for pneumonia (inactivated by lung surfactant). |
| MRSA bacteremia / sepsis | IV vancomycin (AUC-guided where available) or daptomycin in selected cases | Repeat blood cultures, evaluate for endocarditis and metastatic foci, ensure source control. |
| Infective endocarditis (suspected MRSA) | IV vancomycin (or daptomycin in appropriate right contexts) | Early ID consult; prolonged IV therapy is common. |
| Osteomyelitis / deep hardware-associated infection | Often starts with IV vancomycin; step-down/alternatives based on susceptibilities and source control | Surgery/debridement and hardware decisions are often decisive. |
| Post-op/device-associated hospital infection with MRSA risk | Vancomycin-based empiric coverage pending cultures | Narrow promptly once microbiology returns. |
Book support for above options and principles:
- ROSEN's Emergency medicine Concepts and clinical practice, p. 2401 to 2402
- Sherris & Ryan's Medical Microbiology, Eighth Edition, p. 984
- Harrison’s Principles of Internal Medicine 22E, p. 1195 to 1196
Recent-evidence note:
- Recent systematic review/meta-analysis signals in the past 2 years include PMIDs 38145631 and 38789000 (special populations/comparative antibiotic effectiveness). No major contradiction to core textbook framework in this quick check.
If you want, I can turn this into a one-page rapid revision sheet (very exam-focused, with mnemonics and "most tested pitfalls").
This is a shared conversation. Sign in to Orris to start your own chat.